研飞ivySCI (青藤学术）

The Lancet Respiratory Medicine

短名	Lancet Respir. Medicine
Journal Impact	38.76
国际分区	RESPIRATORY SYSTEM(Q1)
期刊索引	SCI Q1中科院 1 区

ISSN	2213-2600, 2213-2619
h-index	182
国内分区	医学(1区)医学危重病医学(1区)医学呼吸系统(1区)
Top期刊	是

柳叶刀呼吸内科对呼吸内科和重症监护的所有领域提供全面的、以临床为中心的报道，包括但不限于：慢性阻塞性肺病、哮喘、囊性纤维化、IPF、肺炎、流感、肺结核、结节病、肺动脉高压、睡眠医学、呼吸道感染、肺血管疾病、肺癌、烟草控制、胸外科和重建手术、间皮瘤和姑息治疗。延续《柳叶刀》出版影响医学实践的高影响力内容的传统，《柳叶刀呼吸医学》的每个月刊都包含原创研究、评论、个人观点、评论和新闻。《柳叶刀呼吸医学》经过严格编辑和同行-审查以确保其多样化内容的科学价值和临床相关性。原始研究在提交后的 8 周内快速发布（平均），并在印刷之前先在 WWW.THELANCET.COM 上在线发表。现在被 PUBMED 索引、JOURNAL CITATION REPORTS® 和 SCOPUS，该期刊接受原始研究、评论、个人观点和评论的提交。访问 HTTP://EES.ELSEVIER.COM/THELANCETRM 以了解有关我们的编辑范围和目标的更多信息，并提交您的手稿。GOLD 或 GREEN OPEN ACCESS 可用于与 ELSEVIER 有协议的选定资助机构支持的研究。该期刊也可免费提供给读者通过 HINARI 计划或通过访问 WWW.THELANCET.COM 的 IP 访问中低收入国家。要了解有关《柳叶刀》呼吸医学的更多信息，请访问 WWW.THELANCET.COM/RESPIRATORY。

期刊主页投稿网址

涉及主题	医学生物内科学病理重症监护医学化学生物化学心理学政治学法学精神科免疫学外科遗传学疾病梅德林哲学
出版信息	出版商: Elsevier Ltd，出版周期: ，期刊类型: journal
基本数据	创刊年份: 2013，原创研究文献占比: 90.53%，自引率:1.80%， Gold OA占比: 32.20%

期刊引文格式

这些示例是对学术期刊文章的引用，以及它们应该如何出现在您的参考文献中。

并非所有期刊都按卷和期组织其已发表的文章，因此这些字段是可选的。有些电子期刊不提供页面范围，而是列出文章标识符。在这种情况下，使用文章标识符而不是页面范围是安全的。

只有1位作者的期刊

有2位作者的期刊

有3位作者的期刊

有5位以上作者的期刊

书籍引用格式

以下是创作和编辑的书籍的参考文献的示例。

学位论文引用格式

网页引用格式

这些示例是对网页的引用，以及它们应该如何出现在您的参考文献中。

专利引用格式

Further insights into MARS 2 – Authors' reply

2024-9-1

Savolitinib in NSCLC: progress in the MET exon 14 journey

2024-9-1

Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study

2024-9-1

Top ten research priorities for sepsis research: UK James Lind Alliance priority setting partnership

2024-9-1

Early exposure to general anaesthesia: considerations for age-related vulnerability and behavioural outcomes

2024-9-1

Further insights into MARS 2

2024-9-1

Further insights into MARS 2

2024-9-1

Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial

2024-9-1

Plinabulin, a microtubule destabilising agent, in non-small-cell lung cancer: lessons from the DUBLIN-3 trial

2024-9-1

Mirtazapine to alleviate severe breathlessness in patients with COPD or interstitial lung diseases (BETTER-B): an international, multicentre, double-blind, randomised, placebo-controlled, phase 3 mixed-method trial

2024-9-1

The ongoing battle against breathlessness

2024-9-1

Respiratory syncytial virus infections in adults: a narrative review

2024-9-1

Extreme heat: holistic thinking in respiratory medicine

2024-9-1

Long-term outcomes of early exposure to repeated general anaesthesia in children with cystic fibrosis (CF-GAIN): a multicentre, open-label, randomised controlled phase 4 trial

2024-9-1

Further insights into MARS 2

2024-9-1

Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months

2024-9-1

PROMISing results for inhaled antibiotics in bronchiectasis

2024-9-1

Influenza-associated and COVID-19-associated pulmonary aspergillosis in critically ill patients

2024-9-1

US FDA approves menthol e-cigarette products

2024-9-1

Louis Bont – leading efforts to find an RSV vaccine

2024-9-1

Early-life respiratory syncytial virus disease and long-term respiratory health

2024-9-1

Choice overload for RSV prevention—how to form your opinion

2024-9-1

Continuing ECMO with no possible transition to recovery or transplant

2024-9-1

ECMO: more than just a bridge over troubled waters?

2024-9-1

Patient-reported outcomes: missing in asthma remission

2024-8-1

Evaluation of elexacaftor–tezacaftor–ivacaftor treatment in individuals with cystic fibrosis and CFTRN1303K in the USA: a prospective, multicentre, open-label, single-arm trial

2024-8-1

An international consensus on the use of asthma biologics in pregnancy

2024-8-1

Whooping cough cases rising

2024-8-1

Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab–ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial

2024-8-1

Fatal dyspnoea at the Palace of Versailles

2024-8-1

High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial

2024-8-1

FLiRTing with danger as SARS-CoV-2 variants evolve

2024-8-1

Estimated number of lives directly saved by COVID-19 vaccination programmes in the WHO European Region from December, 2020, to March, 2023: a retrospective surveillance study

2024-8-1

New thinking and a new direction in bronchiectasis

2024-8-1

Efficacy and safety of gefapixant in women with chronic cough and cough-induced stress urinary incontinence: a phase 3b, randomised, multicentre, double-blind, placebo-controlled trial

2024-8-1

Expanding the indication of CFTR modulator combinations for people with cystic fibrosis with non-F508del variants

2024-8-1

Navigating uncertainty: asthma biologics during pregnancy

2024-8-1

The recent explosion in snortable energy powder consumption

2024-8-1

The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study

2024-8-1

New strategies for patients with limited-stage small-cell lung cancer

2024-8-1

Easing the stress of chronic cough

2024-8-1

When to intubate in acute hypoxaemic respiratory failure? Options and opportunities for evidence-informed decision making in the intensive care unit

2024-8-1

Anti-CTLA-4 in non-small-cell lung cancer: insights from the NIPPON study

2024-8-1

Nasal sprays and behavioural interventions compared with usual care for acute respiratory illness in primary care: a randomised, controlled, open-label, parallel-group trial

2024-8-1

Compassionate use trials and equitable access to variant-specific treatment for cystic fibrosis

2024-8-1

Impact of COVID-19 vaccination programmes in Europe: lives saved and lessons learned

2024-8-1

Saving lives with oxygen and monocytes at Edinburgh Fringe

2024-8-1

The UK COVID-19 Inquiry and critical care

2024-8-1

One lung but many laughs at the Edinburgh Festival Fringe

2024-8-1

Household air pollution: a neglected threat

2024-7-30

帮你贴心管理全部的文献
研飞ivySCI，高效的论文管理

投稿经验分享

分享我的经验，帮你走得更远

The Lancet Respiratory Medicine

期刊引文格式

只有1位作者的期刊

有2位作者的期刊

有3位作者的期刊

有5位以上作者的期刊

书籍引用格式

学位论文引用格式

网页引用格式

专利引用格式

最新文章

Further insights into MARS 2 – Authors' reply

Savolitinib in NSCLC: progress in the MET exon 14 journey

Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study

Top ten research priorities for sepsis research: UK James Lind Alliance priority setting partnership

Early exposure to general anaesthesia: considerations for age-related vulnerability and behavioural outcomes

Further insights into MARS 2

Further insights into MARS 2

Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial

Plinabulin, a microtubule destabilising agent, in non-small-cell lung cancer: lessons from the DUBLIN-3 trial

Mirtazapine to alleviate severe breathlessness in patients with COPD or interstitial lung diseases (BETTER-B): an international, multicentre, double-blind, randomised, placebo-controlled, phase 3 mixed-method trial

The ongoing battle against breathlessness

Respiratory syncytial virus infections in adults: a narrative review

Extreme heat: holistic thinking in respiratory medicine

Long-term outcomes of early exposure to repeated general anaesthesia in children with cystic fibrosis (CF-GAIN): a multicentre, open-label, randomised controlled phase 4 trial

Further insights into MARS 2

Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months

PROMISing results for inhaled antibiotics in bronchiectasis

Influenza-associated and COVID-19-associated pulmonary aspergillosis in critically ill patients

US FDA approves menthol e-cigarette products

Louis Bont – leading efforts to find an RSV vaccine

Early-life respiratory syncytial virus disease and long-term respiratory health

Choice overload for RSV prevention—how to form your opinion

Continuing ECMO with no possible transition to recovery or transplant

ECMO: more than just a bridge over troubled waters?

Patient-reported outcomes: missing in asthma remission

Evaluation of elexacaftor–tezacaftor–ivacaftor treatment in individuals with cystic fibrosis and CFTRN1303K in the USA: a prospective, multicentre, open-label, single-arm trial

An international consensus on the use of asthma biologics in pregnancy

Whooping cough cases rising

Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab–ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial

Fatal dyspnoea at the Palace of Versailles

High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial

FLiRTing with danger as SARS-CoV-2 variants evolve

Estimated number of lives directly saved by COVID-19 vaccination programmes in the WHO European Region from December, 2020, to March, 2023: a retrospective surveillance study

New thinking and a new direction in bronchiectasis

Efficacy and safety of gefapixant in women with chronic cough and cough-induced stress urinary incontinence: a phase 3b, randomised, multicentre, double-blind, placebo-controlled trial

Expanding the indication of CFTR modulator combinations for people with cystic fibrosis with non-F508del variants

Navigating uncertainty: asthma biologics during pregnancy

The recent explosion in snortable energy powder consumption

The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study

New strategies for patients with limited-stage small-cell lung cancer

Easing the stress of chronic cough

When to intubate in acute hypoxaemic respiratory failure? Options and opportunities for evidence-informed decision making in the intensive care unit

Anti-CTLA-4 in non-small-cell lung cancer: insights from the NIPPON study

Nasal sprays and behavioural interventions compared with usual care for acute respiratory illness in primary care: a randomised, controlled, open-label, parallel-group trial

Compassionate use trials and equitable access to variant-specific treatment for cystic fibrosis

Impact of COVID-19 vaccination programmes in Europe: lives saved and lessons learned

Saving lives with oxygen and monocytes at Edinburgh Fringe

The UK COVID-19 Inquiry and critical care

One lung but many laughs at the Edinburgh Festival Fringe

Household air pollution: a neglected threat

帮你贴心管理全部的文献.css-5myebc{font-size:14px;font-weight:var(--chakra-fontWeights-normal);margin-top:var(--chakra-space-1);margin-bottom:var(--chakra-space-1);}研飞ivySCI，高效的论文管理

帮你贴心管理全部的文献
研飞ivySCI，高效的论文管理